Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Gilead Sciences Inc (GILD)

Gilead Sciences Inc (GILD)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 136,384,368
  • Shares Outstanding, K 1,243,929
  • Annual Sales, $ 28,754 M
  • Annual Income, $ 480,000 K
  • EBIT $ 8,221 M
  • EBITDA $ 10,988 M
  • 60-Month Beta 0.29
  • Price/Sales 4.96
  • Price/Cash Flow 16.67
  • Price/Book 7.48

Options Overview Details

View History
  • Implied Volatility 31.80% ( +3.76%)
  • Historical Volatility 25.98%
  • IV Percentile 80%
  • IV Rank 43.23%
  • IV High 49.97% on 04/08/25
  • IV Low 17.95% on 11/07/24
  • Put/Call Vol Ratio 0.60
  • Today's Volume 18,219
  • Volume Avg (30-Day) 24,157
  • Put/Call OI Ratio 0.71
  • Today's Open Interest 249,100
  • Open Int (30-Day) 263,907

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 28 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/25
See More
  • Average Estimate 2.01
  • Number of Estimates 8
  • High Estimate 2.25
  • Low Estimate 1.90
  • Prior Year 2.01
  • Growth Rate Est. (year over year) unch

Price Performance

See More
Period Period Low Period High Performance
1-Month
104.46 +4.96%
on 06/25/25
114.87 -4.55%
on 07/10/25
+0.34 (+0.31%)
since 06/11/25
3-Month
93.37 +17.43%
on 04/25/25
114.87 -4.55%
on 07/10/25
+6.01 (+5.80%)
since 04/11/25
52-Week
69.91 +56.83%
on 07/12/24
119.96 -8.60%
on 03/10/25
+39.67 (+56.70%)
since 07/11/24

Most Recent Stories

More News
S&P 500 and Nasdaq composite pull back from their all-time highs

Stocks closed lower on Wall Street, pulling the S&P 500 and the Nasdaq composite below the records they set a day earlier

NVDA : 164.92 (+0.50%)
META : 717.51 (-1.34%)
C : 86.73 (-0.40%)
$SPX : 6,259.75 (-0.33%)
JPM : 286.86 (-0.46%)
$IUXX : 22,780.60 (-0.21%)
DAL : 56.65 (-0.23%)
LEVI : 21.95 (+11.25%)
PSMT : 108.17 (+5.33%)
WFC : 82.55 (+0.23%)
$DOWI : 44,371.51 (-0.63%)
GILD : 109.64 (-4.28%)
Gilead Sciences Rallies 27.2% in Six Months: Buy or Sell the Stock?

Shares of Gilead Sciences, Inc. GILD have gained 27.2% in the past six months against the industry’s decline of 2.2%. The stock has also outperformed the sector and the S&P 500 index in this time frame.Gilead...

MRK : 83.36 (-0.79%)
GILD : 109.64 (-4.28%)
GSK : 38.28 (-3.28%)
Better Dividend ETF to Buy for Passive Income: SCHD or GCOW

MO : 57.80 (-1.28%)
CSCO : 67.95 (-1.18%)
VZ : 41.62 (-0.98%)
KO : 69.87 (+0.14%)
CVX : 155.31 (+0.74%)
GCOW : 38.75 (-0.44%)
COP : 95.61 (+0.25%)
SCHD : 27.33 (-0.65%)
NVS : 121.02 (-2.19%)
TXN : 221.25 (+0.72%)
AMGN : 295.27 (-1.70%)
NSRGY : 96.5200 (-1.08%)
Gilead Sciences: A Mixed Bag of Opportunities and Risks

GILD : 109.64 (-4.28%)
The Saturday Spread: Data-Driven Trades That Cut Through the Noise (GILD, MCD, DJT)

This weekend’s edition identifies three hot stocks that are flashing above-average upside probabilities with compelling multi-leg options strategies.

GILD : 109.64 (-4.28%)
MCD : 299.91 (+0.51%)
DJT : 18.52 (-2.17%)
FDA Approves Gilead's Twice-Yearly Shot for HIV Prevention

Gilead Sciences, Inc. GILD obtained FDA approval for its twice-yearly injectable HIV-1 capsid inhibitor, lenacapavir, for the prevention of HIV.The regulatory body approved lenacapavir, under the brand...

BAYRY : 7.9800 (-1.72%)
NVS : 121.02 (-2.19%)
GILD : 109.64 (-4.28%)
GSK : 38.28 (-3.28%)
The world's only twice-a-year shot to prevent HIV could stop transmission — if people can get it

The Food and Drug Administration has approved the world’s only twice-a-year shot to prevent HIV

GILD : 109.64 (-4.28%)
Is Biogen Stock Underperforming the S&P 500?

Biogen has significantly underperformed the S&P 500 over the past year, but analysts are moderately optimistic about the stock’s prospects.

$SPX : 6,259.75 (-0.33%)
GILD : 109.64 (-4.28%)
BIIB : 134.21 (-0.83%)
FDA Places Clinical Hold on Gilead's HIV Studies, Stock Down

Gilead Sciences, Inc. GILD announced that the FDA has placed a clinical hold on studies on pipeline candidates, GS-1720 and/or GS-4182, for the treatment of HIV.GS-1720 is an investigational integrase...

BAYRY : 7.9800 (-1.72%)
NVS : 121.02 (-2.19%)
GILD : 109.64 (-4.28%)
GSK : 38.28 (-3.28%)
Why Gilead Scinces Stock Tumbled on Tuesday

NFLX : 1,245.11 (-0.44%)
NVDA : 164.92 (+0.50%)
$SPX : 6,259.75 (-0.33%)
GILD : 109.64 (-4.28%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Buy with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More Share

Business Summary

Gilead Sciences is a pioneer in developing drugs for the treatment of human immunodeficiency virus, liver diseases, hematology/oncology diseases and inflammation/respiratory diseases. The company has a strong HIV franchise with key HIV/AIDS therapies like tenofovir alafenamide based products - Genvoya,...

See More

Key Turning Points

3rd Resistance Point 116.84
2nd Resistance Point 115.33
1st Resistance Point 112.48
Last Price 109.64
1st Support Level 108.12
2nd Support Level 106.61
3rd Support Level 103.76

See More

52-Week High 119.96
Last Price 109.64
Fibonacci 61.8% 100.84
Fibonacci 50% 94.93
Fibonacci 38.2% 89.03
52-Week Low 69.91

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar